STATIN-FIBRATE REPORT: Focus on Safety

There were no cases of myopathy seen with resins or niacin in this analysis. The authors concluded that there is an increased risk for myopathy in patients receiving lipid-lowering agents, with fibrates being associated with the greatest risk. However, the absolute risk of myopathy with lipid-lowering agents (statin and fibrates) is small. ................
................

In order to avoid copyright disputes, this page is only a partial summary.